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Surgery for 
infective endocarditis
susceptibility to antibiotics (2) Haemodynamic sequela related 
mainly to valvular insuffi ciency but including valve obstruction 
(so called Oslerian endocarditis) and rupture of fi stulae into the 
systemic venous or pulmonary arterial circulation and (3) Systemic 
embolism and the potential for recurrence.  Figure 1 depicts the 
variable contribution of each of these categories and serves to 
emphasise the fact that systemic embolism is the least important, 
and also the most controversial indication for surgery.
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INFECTIVE 
ENDOCARDITIS
INTRODUCTION                                                              
Despite advances in antimicrobial chemotherapy, infective endo-
carditis (IE) remains a lethal disease with a case fatality rate of 
almost 40%.(1,2) Surgery may be life saving, but the indication and 
timing for it are controversial. While much of our practice in 
cardiology is governed by the results of randomised control 
trials – the most rigorous test of the value of an intervention – this 
has not been possible when testing the role of surgery for IE. 
Reasons for this include logistical diffi culties, the relatively low 
incidence of the disease in single centers and clinical hetero-
geneity.  The European and American heart association guidelines 
provide a framework for surgical intervention in IE,(3,4) but it 
should be borne in mind that they are not based on level I 
evidence and that while they are useful, they do not replace 
mature and experienced clinical judgment.
SURGERY FOR NATIVE MITRAL AND AORTIC            
VALVE ENDOCARDITIS
In essence, the need for surgery in patients with IE is determined 
by the interaction of three factors (1) Organism-related factors 
including virulence, propensity to cause local destruction and 
The last decade has seen many changes in the landscape of 
infective endocarditis (IE) – ranging from the epidemiology, 
microbiology, diagnostic techniques and indication for 
antibiotic prophylaxis.  Unfortunately, the role of surgery in 
the patient with endocarditis, including the indication, 
timing and type of surgery continues to be plagued by 
controversy. Although surgery has an important and 
established role in critically ill patients with endocarditis, 
the choice between medical therapy and surgery is often 
less clear cut and poses a major challenge to the physician 
treating this condition. The following article summarises 
some of these controversies including indications for 
surgery in native and prosthetic valve endocarditis, the 
timing of surgery, the choice of prostheses and issues 
surrounding anti-coagulation. SAHeart 2009; 6:84-89
FIGURE 1: Indications for surgery for infective endocarditis.
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Factors related to the infecting organism
As a consequence of the capacity for extensive local tissue 
destruction or resistance to antibiotics, infection with certain 
organisms may predict a high likelihood that surgical intervention 
will be required.
Coagulase positive and negative staphylococcal infection is 
notorious for extensive tissue breakdown, local spread and a 
predilection for abcess and fi stula formation.  In many Western 
populations, S. Aureus is now the leading cause of nosocomial 
and community acquired health care associated endocarditis and 
the second commonest cause of non-health care associated 
IE.(5) Apart from the intrinsic virulence of staphylococci, several 
other factors combine to increase the mortality (about 50%) 
of medically treated staphyloccocal endocarditis.(6)  These include 
older age with atypical presentation, presence of co-morbid 
disease and a rising incidence of resistance not only to the beta-
lactams, but also to vancomycin.(7) Infection extending beyond 
the valve leafl ets occurs in 10-20% of patients and affects the 
aortic valve more commonly than the mitral.  Perivalvular abcess 
formation is an indication for urgent surgery. Persistent fever, 
appearance of new electrocardiographic conduction defects and 
pericarditis are clues to the presence of peri-aortic suppuration 
but lack sensitivity.  The threshold to performing transesophageal 
echocardiography should be low and may allow earlier diagnosis 
(Figure 2).
Other organisms that are associated with a poor outcome with 
medical treatment include Streptococcus pneumonia, Group B 
streptococci, enterococci, gram negative bacilli, brucella and fungal 
endocarditis.  The overall medical cure rate for fungal endocarditis 
is only 14%(8) and is due in part to poor penetration of anti-
fungal agents into the vegetation, the low toxic-therapeutic ratio 
of currently available agents and the common lack of fungicidal 
activity. A cure is virtually impossible without surgical inter-
vention.  The role of newer anti-fungal agents such as caspofungin 
and voriconazole is as yet undefi ned.
Irrespective of the organism, microbiologic or clinical evidence of 
persistent and uncontrolled infection despite appropriate anti-
biotics is a relative indication for surgery.  Thus, surgery should be 
considered in a patient with persistently positive blood cultures 
or fever despite one week of antibiotic therapy after other 
aetiologies such as metastatic abcess, drug fever and confounding 
secondary infections have been ruled out.
Surgical intervention is also indicated for most patients with 
culture negative IE who exhibit evidence of persistent uncontrolled 
infection (fever for more than 7-10 days) without evidence of 
infection at another site.
Relapse of patients with native valve IE after adequate therapy 
may require surgical intervention, although a second course of 
antibiotics may be reasonable if there is no paravalvular suppura-
tion and the causative organism is sensitive to antibiotics. It is 
important, however, to differentiate relapse from re-infection
where a further course of antibiotics could be considered.
High levels of C-reactive protein after one week of antibiotic 
therapy have recently been found to predict serious complica-
tions and death from IE with an odds ratio of 10.3 in patients in 
the highest tertile versus the lowest tertile.(9)  While some studies 
have found C-reactive protein a useful predictor of need for surgery, 
this has not been a consistent fi nding.
Haemodynamic factors
The greatest benefi ts of surgery have been noted in patients 
with IE and heart failure that is almost always due to severe 
FIGURE 2: Transesophageal basal 4 chamber view showing 
circumferential perivalvular abcess (arrow).  AV=aortic valve
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valvular insuffi ciency. Rarely, heart failure may be due to large 
obstructive vegetations. While antibiotic therapy is generally 
successful in curing infection, it can hardly be expected to make 
any impact on a valve that is already severely incompetent.  Prior 
to the routine use of surgery, heart failure was responsible for 
almost 90% of deaths from IE.  Mortality from medically treated 
heart failure in IE is 75% and can be reduced to 25% with 
surgical intervention.(10-13)  In a more recent report, Slater et al. 
documented their experience in 364 patients with IE seen over 
a 10 year period.(14)  Heart failure was the indication for surgery 
in 52% of their patients and the presence of haemodynamic 
instability was an independent predictor of mortality.  Surgery 
was associated with a signifi cantly improved short and long 
term survival.
While most reports have confi rmed the benefi ts of surgery in 
high risk patients with IE, a recent publication from the Mayo 
clinic failed to document any advantage, and suggested perhaps 
even an increased mortality in individuals having operative 
intervention.(15) Although the study used a propensity score to 
match surgical and non-surgical patients, it is arguable whether 
this technique is able to prevent completely the infl uence of 
selection bias.
Acute aortic regurgitation constitutes a more precarious hae-
modynamic state than mitral regurgitation and is a reason to 
consider emergency surgery.  It has always been our policy to 
submit these patients for surgery within 24-48 hours of starting 
antibiotics with excellent long term results.(16)  Echocardiography 
is useful to identify patients with acute severe aortic regurgi-
tation(17) due to IE by demonstrating premature closure of the 
mitral valve on M-Mode (Figure 3a) and diastolic mitral regurgi-
tation with combined M-Mode and color fl ow imaging or pulsed 
Doppler (Figure 3b).  It is important that other causes of heart 
failure such as sepsis, anaemia and pre-existing left ventricular 
dysfunction be ruled out before implicating valvular regurgitation 
as the mechanism.
A more controversial indication for surgery is the patient with 
severe mitral or aortic regurgitation but without clinical heart 
failure.  While the ACC/AHA guidelines list this as a relative 
indication for surgery,(4) the absolute benefi ts may not be 
evident especially where operative intervention entails replace-
ment with a mechanical prosthetic valve with the attendant risks 
of prosthetic valve endocarditis, thrombosis, embolism and 
anticoagulant related bleeding.  We therefore believe that these 
patients should be closely monitored and the need for surgery 
dictated by concomitant factors which require surgery in their 
own right.
INFECTIVE ENDOCARDITIS
FIGURE 3a: M-Mode through the mitral valve in a patient with 
aortic valve endocarditis and acute severe aortic regurgitation 
showing premature closure of the mitral valve.
FIGURE 3b: Spectral Doppler in same patient showing diastolic 
mitral regurgitation.
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Embolic complications
Clinical systemic embolisation is seen in 10-35% of patients 
although occult events may occur more frequently.(18)  The signifi -
cance of echocardiographically detected vegetations as a risk 
factor for systemic embolism is controversial.  The presence of 
large vegetations does, however, appear to be predictive of 
increased morbidity, need for surgery and mortality.
The best treatment for echocardiographically detected vegeta-
tions is not surgery, but prompt and appropriate antibiotic 
therapy following which clinically evident embolisation is unusual. 
The literature, however, is replete with studies examining the 
value of a variety of echocardiographic characteristics of vegeta-
tions such as mobility and size which may predict risk of embolisa-
tion and need for surgery.  Despite a strong direct association 
between vegetation size and risk for thromboembolism, not all 
patients with large vegetations invariably have a stroke and 
conversely, some patients with relatively small vegetations suffer 
disabling events.  Non-vegetation related predictors of embolism 
include age, staphylococcal infection and high CRP.  Thus, in 
general, vegetation size alone should not be a reason for surgical 
intervention but in conjunction with other factors such as 
persistent sepsis or valve dysfunction, may lower the threshold 
for operation.
Recurrent systemic embolism despite appropriate antibiotic 
therapy is an indication for surgery, but there is no consensus 
on what the defi nition of recurrent should be.  Most authors 
would concur that two or more episodes occurring during anti-
biotic therapy represents a reasonable indication for surgery.(19)
SURGERY FOR PROSTHETIC  VALVE                           
ENDOCARDITIS
By its very nature, prosthetic valve endocarditis (PVE) is a more 
serious disease than native valve IE with an overall mortality of 
almost 33%.  Early PVE (defi ned as occurring within 60 days 
of surgery) carries a much higher mortality than late PVE, 
mainly because of a greater incidence of coagulase positive and 
negative staphylococcal infection. As with native valve IE, heart 
failure and staphylococcal infection are independent predictors 
of mortality(20) but there are several complications that are 
unique to PVE.  These include valve dehiscence, paraprosthetic 
ring leaks and mechanical dysfunction of the prosthesis.  While 
transoesophageal echocardiography is important in the diagnosis 
and management of IE,(21) it fi nds particular value, and is 
mandatory, in patients with PVE in whom vegetations, abcesses, 
fi stulae and ring leaks may not be visualised by any other 
technique.
A medical cure is far less likely with PVE.  The recommendations 
for surgery are the same for native valve IE but additional indica-
tions include prosthetic valve dysfunction and an unstable pros-
thesis, both of which constitute an indication for urgent operative 
intervention.
Unfortunately, for a number of reasons, the risks of surgery are 
also higher for PVE than for native valve IE.  These include the 
additional risk associated with re-operation, more aggressive 
perivalvular suppuration requiring more complex surgery and 
the inability to perform valve repair as with native valve IE.
TIMING OF SURGERY                                                      
If the indications for surgery are controversial, the decision as 
to when to operate in patients with IE may be even more 
diffi cult, requiring greater clinical judgment. Many of the compli-
cations of IE are sudden, catastrophic and often fatal, and the 
decision not to have operated earlier is not infrequently regretted. 
On the other hand, physicians frequently prefer to optimise 
patients medically and institute antibiotic therapy in order to 
sterilise the area of planned surgical intervention.  Contrary to 
popular belief, however, surgery is not contraindicated in the 
presence of active infection and in fact may be life saving.  Critically 
ill patients in whom antimicrobial therapy has not yet been 
initiated, should be commenced immediately on broad spectrum 
antibiotics after blood cultures have been drawn and monitored 
intensively thereafter.  Any deterioration, or failure to improve 
after 24-48 hours of treatment requires prompt surgical interven-
tion providing the previously discussed indications are met.  This 
approach requires a multi-disciplinary approach with early and 
close interaction between cardiologist, cardiothoracic surgeon 
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and microbiologist. The indications for surgery according to 
urgency are listed in Table I.
ASPECTS OF SURGERY FOR INFECTIVE                    
ENDOCARDITIS
Surgical technique and choice of prosthesis
Details of operative approach are better covered in surgical 
texts. A fundamental principle of surgery, however, is radical 
debridement and extirpation of all infected tissue so that the 
new valve may be implanted on strong and healthy tissue.  Surgical 
reconstruction of the aortic root for peri-aortic suppuration, 
sometimes with almost complete aorto-left ventricular disconti-
nuity, poses a tremendous challenge, but equally challenging is 
resection of abcesses located in the posterior mitral annulus and 
in the aorto-mitral curtain.(22)
Aortic valve repair is rarely an option and the choice of pros-
thesis in this position is a matter of some debate.  However, 
most surgeons agree that scrupulous removal of all infected 
tissue is probably more important than the type of valve 
selected.(22)  Homografts may be more resistant to re-infection 
but their main advantage seems to be that they are ideally suited 
to reconstructing the aortic root, ease of handling and the ability 
to use the remnant of the anterior mitral valve for patching 
defects created by resection of abcesses.(22)  Although the risk 
of recurrent IE appears to be similar for mechanical and biopros-
thetic valves,(23) the Toronto group prefer mechanical valves 
because of easier implantation.(22)
As for surgery for mitral regurgitation not associated with IE, 
repair is preferable to replacement provided the surgeon can 
guarantee with a high degree of probability that the patient will 
not be left with anything more than mild residual regurgitation. 
Not infrequently, infection may spread onto the chordae and 
papillary muscle and it is imperative that this be debrided.
Importantly, surgeons need to be reminded that all resected 
tissue be submitted for culture and histology.  Following surgery, 
antibiotics should be continued for the planned total duration of 
4-6 weeks, but where the valve culture is positive, the ESC guide-
lines recommend another full course of antimicrobial therapy.(3)
Surgery for infective endocarditis complicated by stroke
The decision regarding cardiac surgery in the patient with IE 
already complicated by a stroke may be particularly diffi cult.  Apart 
from the ethical issue of submitting a patient for a major cardiac 
procedure who may have suffered substantial neurologic damage 
from which recovery may be unlikely, the risk benefi t ratio of 
converting an ischaemic infarct into a haemorrhagic one or 
extending an intracerebral bleed during cardiopulmonary bypass 
have to be carefully considered.  Recommendations regarding 
the optimal timing of surgery after cerebral infarction range from 
immediate,(24) if the reason for cardiac surgery is compelling, up 
to 4 weeks.(25)  An additional factor to consider in the timing of 
surgery is the continued presence of a large mobile vegetation 
with a high likelihood of further embolism.  In the Japanese study(25) 
of 181 patients with IE and stroke, 44% had further neurologic 
deterioration if a non-haemorrhagic cerebral event had occurred 
within 7 days of surgery, compared with only 2.3% experiencing 
deterioration if surgery was delayed by 4 weeks.  In haemorrhagic 
stroke, the risk persisted for up to 4 weeks.  The consensus of 
opinion seems to be to delay surgery up to 2 weeks for a non-
INFECTIVE ENDOCARDITIS
TABLE 1:  Indications for surgery in infective endocarditis according 
to urgency
Emergency surgery (< 24 hours) 
Aortic regurgitation with acute severe heart failure
Rupture of a sinus of  Valsalva into adjacent structures
Prosthetic valve malfunction
Prosthetic valve dehiscence
Urgent surgery (24-72 hours)
Perivalvular abcess
Severe mitral or aortic regurgitation with heart failure
Non urgent surgery
Persistent fever despite appropriate antibiotics
Recurrent cerebral emboli
Resistant organisms – Staphylococci, Fungi
Relapse after previous antibiotic treatment
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haemorrhagic cerebral event and up to a month for an intra-
cerebral bleed.  Patients with an intracerebral bleed should have 
conventional cerebral or magnetic resonance angiography in 
order to detect ongoing bleeding from a ruptured aneurysm.  If 
present, this should be corrected prior to cardiac surgery. 
Anticoagulation issues
Patients with PVE on chronic Warfarin anticoagulation should 
be switched to unfractionated or low molecular weight heparin 
if surgery is anticipated.  If a neurologic event has already occurred 
in a patient on chronic warfarin therapy, it is important to docu-
ment by means of brain CT or MRI the presence of a bleed.  If a 
bleed is confi rmed, all anticoagulation should be stopped since 
the risk of further intracerebral bleeding outweighs the risk of 
prosthetic valve thrombosis, but the duration of cessation should 
be individualised for each patient.
CONCLUSION                                                                   
The fact that the role of surgery for IE is surrounded by some 
controversy should not detract from the important contribution it 
makes to the management of these patients.  In patients with 
acute severe aortic regurgitation, refractory heart failure related 
to signifi cant mitral or aortic regurgitation and those with 
advanced and locally destructive complications, surgery may be 
life saving.
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